Phyllis Fung-Yi Cheung

Phyllis Fung-Yi Cheung

Auto-generated profile, based on publicly available information

Phyllis Fung-Yi Cheung

Spatiotemporal Tumor Heterogeneity, German Cancer Consortium (DKTK), Partner Site Essen, A Partnership Between German Cancer Research Center (DKFZ) and University Hospital Essen Essen Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in Allergy
Verified
Journal Article
Open access
PDF file
DHDanqi Huang
Danqi Huang
XLXiuting Liu
Xiuting Liu
XGXun Gao
Xun Gao
CCChun Kit Choi
Chun Kit Choi
GGGiovanni Giglio
Giovanni Giglio
CWChun-Kwok Wong
Chun-Kwok Wong
Background: Meteorin‐like protein (METRNL)/Interleukin‐41 (IL‐41) is a novel immune‐secreted cytokine/myokine involved in several inflammatory diseases. However, how METRNL exerts its regulatory properties on skin inflammation remains elusive. This study aims to elucidate the functionality and regulatory mechanism of METRNL in atopic dermatitis (AD).Methods: METRNL levels were determined in skin and serum samples from patients with AD and subsequently verified in the vitamin D3 analogue MC903‐induced AD‐like mice model. The cellular target of METRNL activity was identified by multiplex immunostaining, single‐cell RNA‐seq and RNA‐seq.Results: METRNL was significantly upregulated in lesions and serum of patients with dermatitis compared to healthy controls (p <.05). Following repeated MC903 exposure, AD model mice displayed elevated levels of METRNL in both ears and serum. Administration of recombinant murine METRNL protein (rmMETRNL) ameliorated allergic skin inflammation and hallmarks of AD in mice, whereas blocking of METRNL signaling led to the opposite. METRNL enhanced β‐Catenin activation, limited the expression of Th2‐related molecules that attract the accumulation of Arginase‐1 (Arg1)hi macrophages, dendritic cells, and activated mast cells.Conclusions: METRNL can bind to KIT receptor and subsequently alleviate the allergic inflammation of AD by inhibiting the expansion of immune cells, and downregulating inflammatory gene expression by regulating the level of active WNT pathway molecule β‐Catenin.

13 October 2023 in Science Advances
Verified
Journal Article
Open access
Donald CameronDonald Cameron
Donald Cameron
JGJan Grosser
Jan Grosser
SLSwetlana Ladigan
Swetlana Ladigan
VKVladislav Kuzin
Vladislav Kuzin
EIEvanthia Iliopoulou
Evanthia Iliopoulou
LBLaura Baranello
Laura Baranello
Pancreatic carcinoma lacks effective therapeutic strategies resulting in poor prognosis. Transcriptional dysregulation due to alterations in KRAS and MYC affects initiation, development, and survival of this tumor type. Using patient-derived xenografts of KRAS- and MYC-driven pancreatic carcinoma, we show that coinhibition of topoisomerase 1 (TOP1) and bromodomain-containing protein 4 (BRD4) synergistically induces tumor regression by targeting promoter pause release. Comparing the nascent transcriptome with the recruitment of elongation and termination factors, we found that coinhibition of TOP1 and BRD4 disrupts recruitment of transcription termination factors. Thus, RNA polymerases transcribe downstream of genes for hundreds of kilobases leading to readthrough transcription. This occurs during replication, perturbing replisome progression and inducing DNA damage. The synergistic effect of TOP1 + BRD4 inhibition is specific to cancer cells leaving normal cells unaffected, highlighting the tumor’s vulnerability to transcriptional defects. This preclinical study provides a mechanistic understanding of the benefit of combining TOP1 and BRD4 inhibitors to treat pancreatic carcinomas addicted to oncogenic drivers of transcription and replication.

15 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ILI-Na Lu
I-Na Lu
PCPhyllis Fung-Yi Cheung
Phyllis Fung-Yi Cheung
MHMichael Heming
Michael Heming
CTChristian Thomas
Christian Thomas
GGGiovanni Giglio
Giovanni Giglio
GHGerd Meyer zu Hörste
Gerd Meyer zu Hörste
5q-associated spinal muscular atrophy (SMA) is a motoneuron disease caused by mutations in the survival motor neuron 1 (SMN1) gene. Adaptive immunity may contribute to SMA as described in other motoneuron diseases, yet mechanisms remain elusive. Nusinersen, an antisense treatment, enhances SMN2 expression, benefiting SMA patients. Here we have longitudinally investigated SMA and nusinersen effects on local immune responses in the cerebrospinal fluid (CSF) - a surrogate of central nervous system parenchyma. Single-cell transcriptomics (SMA: N = 9 versus Control: N = 9) reveal NK cell and CD8+ T cell expansions in untreated SMA CSF, exhibiting activation and degranulation markers. Spatial transcriptomics coupled with multiplex immunohistochemistry elucidate cytotoxicity near chromatolytic motoneurons (N = 4). Post-nusinersen treatment, CSF shows unaltered protein/transcriptional profiles. These findings underscore cytotoxicity’s role in SMA pathogenesis and propose it as a therapeutic target. Our study illuminates cell-mediated cytotoxicity as shared features across motoneuron diseases, suggesting broader implications.

6 February 2026 in Nature Communications
Verified
Journal Article
Open access
JPJuanFei Peng
JuanFei Peng
JYJiaJin Yang
JiaJin Yang
GAGeorgia Antonopoulou
Georgia Antonopoulou
RFRui Fang
Rui Fang
BABikash Adhikari
Bikash Adhikari
Jens SivekeJens Siveke
Jens Siveke
GATA6 promotes epithelial phenotypes and limits epithelial-to-mesenchymal (EMT) transition in pancreatic ductal adenocarcinoma (PDAC). Here we show that GATA6 defines a tumor cell state that induces MHCI expression and anti-tumor cytotoxicity upon therapy. In human PDAC, GATA6 expression correlates with immune cell infiltration, and spatial analysis reveals interaction between GATA6 + tumor cells and CD8 + T cells. In murine PDAC, MEK inhibition (MEKi) enriches antigenicity-related gene sets in GATA6 high cells, while GATA6 knockout or degradation impairs MEKi-induced MHCI upregulation. High-GATA6 tumors respond to MEKi with increased MHCI, enhancing T-cell cytotoxicity, whereas GATA6 loss abolishes this effect. Treatment-induced EMT reduces GATA6 + populations and MHCI expression, which is restored by combining MEKi with HDAC inhibitors, enhancing GATA6 + tumor cells, MHCI, CD8 + T cell infiltration, tumor suppression, and survival. These findings suggest that therapeutic strategies promoting a GATA6-driven tumor cell state improve immune recognition of PDAC cells and potentiate anti-tumor cytotoxic effects.

21 May 2026 in HLA
Verified
Journal Article
Open access
HKHalime Kalkavan
Halime Kalkavan
AHAndreas Heinold
Andreas Heinold
SLSiyang Liu
Siyang Liu
GBGaurav M. Borse
Gaurav M. Borse
FHFalko M. Heinemann
Falko M. Heinemann
MSMartin Schuler
Martin Schuler
Tebentafusp, a T‐cell receptor‐bispecific molecule targeting glycoprotein 100‐derived peptide presented by HLA class I molecule and CD3, is standard of care for patients with unresectable or metastatic uveal melanoma who are positive for HLA‐A*02:01 . Mechanisms of resistance to tebentafusp are unknown. We report a patient with metastatic uveal melanoma who acquired resistance to tebentafusp after 30 months of treatment. Genomic loss of the HLA‐haplotype carrying the HLA‐A*02:01 restriction element was detected in a progressive metastasis, resulting in loss of presentation of tebentafusp's target antigen. Understanding mechanisms of resistance against synthetic cancer immunotherapies will be key to monitoring disease control and development of early intervention strategies towards cure.